Charles McWherter

Insider Reports History

Entity
Individual
Location
C/O Cymabay Therapeutics, Inc., 7575 Gateway Blvd., Suite 110, Newark, CA
Signature
/s/ Ryan A. Murr, as attorney-in-fact for Charles McWherter
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Charles McWherter:

Stock Role Class Num Shares Value Price $ Report Date Ownership
CymaBay Therapeutics, Inc. President of R&D Common Stock 0 $0 $2.94 Mar 22, 2024 Direct
89bio, Inc. Director Stock Option (Right to Buy) 67.7K Aug 5, 2024 Direct
CymaBay Therapeutics, Inc. President of R&D Employee Stock Option (right to buy) 0 Mar 22, 2024 Direct

Insider Reports Filed by Charles McWherter

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ETNB 89bio, Inc. Aug 5, 2024 1 $0 4 Aug 7, 2024 Director
ETNB 89bio, Inc. Jul 30, 2024 0 $0 3 Aug 7, 2024 Director
CBAY CymaBay Therapeutics, Inc. Mar 22, 2024 13 $0 4 Mar 22, 2024 President of R&D
CBAY CymaBay Therapeutics, Inc. Jan 24, 2024 2 $0 4 Jan 26, 2024 President of R&D
CBAY CymaBay Therapeutics, Inc. Jan 19, 2024 15 -$305K 4 Jan 22, 2024 President of R&D
CBAY CymaBay Therapeutics, Inc. Dec 18, 2023 8 -$187K 4 Dec 18, 2023 President of R&D
CBAY CymaBay Therapeutics, Inc. Nov 17, 2023 6 -$151K 4 Nov 17, 2023 President of R&D
CBAY CymaBay Therapeutics, Inc. Oct 18, 2023 7 -$197K 4 Oct 18, 2023 President of R&D
CBAY CymaBay Therapeutics, Inc. Sep 18, 2023 7 -$244K 4 Sep 19, 2023 President of R&D
CBAY CymaBay Therapeutics, Inc. Aug 18, 2023 7 -$141K 4 Aug 18, 2023 President of R&D
CBAY CymaBay Therapeutics, Inc. Jul 18, 2023 7 -$140K 4 Jul 19, 2023 President of R&D
CBAY CymaBay Therapeutics, Inc. Jun 20, 2023 7 -$68.6K 4 Jun 21, 2023 President of R&D
CBAY CymaBay Therapeutics, Inc. May 18, 2023 7 -$88.6K 4 May 19, 2023 President of R&D
CBAY CymaBay Therapeutics, Inc. Jan 25, 2023 1 $0 4 Jan 27, 2023 President of R&D
CBAY CymaBay Therapeutics, Inc. Jan 25, 2022 1 $0 4 Jan 27, 2022 Chief Scientific Officer